Galenica announces sustained growth in 2023 and optimistic forecasts for 2024

The Galenica Group reported an increase in revenue of 4.4% for the financial year 2023, reaching consolidated net sales of CHF 3,746.0 million. Excluding exceptional COVID-19 sales from the previous year, growth stood at 5.0%. Adjusted EBIT increased slightly by 0.4% to CHF 191.3 million; without certain exceptional factors, this increase would have reached 5.5%, with an adjusted EBIT of CHF 201.1 million. The group is proposing a dividend identical to that of the previous year, i.e. 2.20 CHF per share.

For 2024, Galenica anticipates an increase in revenue of between 3% and 5% and expects adjusted EBIT to grow by 8% to 11%. These forecasts are part of a sustainable dividend growth strategy, with the group aiming for a dividend at least equivalent to that of the previous year.

In 2023, Galenica strengthened its healthcare offering with the founding of Redcare Pharmacy, Switzerland's leading online pharmacy, and expanded its portfolio in the field of complementary medicine with the acquisition of Padma. Initiatives to improve the security of supply of medicines and the continued development of the Documedis® software are among the highlights of the year.

The group highlights its ambition to offer an optimal customer experience, through its stationary pharmacies and their online stores, and plans to optimize and expand its pharmacy network in 2024. Galenica is also committed to the development sustainable, with initiatives such as increasing the use of Clinical Decision Support Checks and commissioning a photovoltaic installation in Niederbipp.